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Purpose: Congenital epidermolysis bullosa (CEB) is a group of rare monogenic genoderma-
toses. Phenotypically, the diseases vary in both severity and dissemination, which complicates 
studies of their epidemiology. To investigate the potential of using the Danish National Patient 
Registry (DNPR) for epidemiological research on CEB, we examined the positive predictive 
value (PPV) of a f﻿irst-time diagnosis of CEB.
Methods: We identif﻿ied patients with a record of CEB in DNPR and the Danish Pathology 
Registry (DPR) during January 1, 1977, until December 31, 2015. We restricted diagnoses 
from two dermatological departments and one regional hospital. Diagnoses in the DNPR are 
coded by the eighth and tenth revisions of the ICD (ICD-8 and ICD-10) and in the DPR by the 
Systematized Nomenclature of Medicine (SNOMED). We used clinical description in medical 
records, family history, histological f﻿indings, and molecular genetic investigations to validate 
diagnoses and classif﻿ied them as rejected and conf﻿irmed. We estimated PPVs for any diagnosis, 
according to coding systems used, and for additional subdivisions of ICD-10 codes.
Results: We identif﻿ied 116 cases from the hospital departments investigated and evaluated 96 
medical records for validity. The overall PPV for probable CEB was 62.5% (95% CI: 52.5–71.5). 
For ICD-8, ICD-10, and SNOMED codes, the PPVs were 30.8% (95% CI: 11.4–57.7), 76.7% 
(95% CI: 65.8–84.9), and 0.0% (95% CI: 0.0–21.7), respectively. For the ICD-10 codes, we 
found the highest PPVs for diagnoses arising from the dermatological departments. For subdi-
visions of ICD-10 codes, PPVs were high for epidermolysis bullosa simplex and dystrophica.
Conclusion: The PPVs for f﻿irst-time diagnoses of CEB registered in the two Danish nationwide 
registries investigated, DNPR and DPR, ranged from low to average. We therefore recommend 
that these data be used with caution and restricted to ICD-10 diagnoses from specialized der-
matological departments.
Keywords: Denmark, diagnosis, epidermolysis bullosa, health administrative data, registra-
tion, validity
Introduction
Congenital epidermolysis bullosa (CEB) is a group of rare genetic skin diseases with 
known monogenetic pathogenesis.1 CEB is characterized by blistering caused by frag-
ile epithelial surfaces in the skin and mucosa.2 It is associated with variable levels of 
morbidity, some of which require highly specialized care.3 The wide range of clinical 
presentations and the limited knowledge on genotype–phenotype correlations make 
further investigations into the epidemiology, pathogenesis, and prognostic factors of 
epidermolysis bullosa (EB) both diff﻿icult and much needed.
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The latest consensus report on the classif﻿ication of CEB 
is from 2014 and was preceded by three earlier reports from 
1991, 2000 and 2008.4–6 The relatively frequent modif﻿ica-
tions of the def﻿initions illustrate uncertainties regarding the 
classif﻿ication of this rare genetic disease.
A rare disease is def﻿ined by the European Union as a 
“life-threatening or chronically debilitating condition” with 
a prevalence below 1:2,000.7 The estimated prevalence of 
CEB ranges from 6:1,000,000 for EB simplex to less than 
1:1,000,000 for junctional EB.8 These prevalence estimates 
are derived from single reports and may generalize poorly 
because of the heterogeneous nature of the diseases and the 
different diagnostic methodologies employed. Furthermore, 
the continuous changes in both the nomenclature and the 
subdivision of EB will impede the strength of epidemiologi-
cal studies merely based on extraction and extrapolation of 
the few existing studies.
It is enticing to use population-based healthcare data-
bases, such as those developed and broadly utilized in 
Denmark, as a cost-effective way to conduct epidemiologi-
cal research on EB. With the whole population as a cohort 
and an uncensored inclusion process, the Danish registries 
provide the potential to obtain precise and unbiased epi-
demiological estimates.9 As the currently implemented 
diagnosis coding system (the tenth revision of the ICD) was 
developed in the late 1980s, epidemiological statements 
and surveillance based on the ICD-10 may lack precision 
compared to current diagnostic consensus. Thus, an assess-
ment of validity of codes for these diseases in the Danish 
registries is essential. We therefore validated f﻿irst-time 
diagnosis of CEB in two Danish patient registries – The 
Danish National Patient Registry (DNPR) and The Dan-
ish Pathology Registry (DPR) – using a review of medical 
records as reference standard.
Methods
Data sources
The Danish National Health Service provides tax-supported 
health care for all Danish residents. This facilitates free and 
unrestricted access to hospitals and treatment. Since 1968, 
each person living in Denmark has been given a unique 
10-digit Civil Personal Registration (CPR) number by the 
Danish Civil Registration System.10 The CPR number allows 
accurate and individualized registrations of visits and diseases 
in various Danish registries. In this study, we used the DNPR 
and the DPR to identify all patients with a f﻿irst-time diagnosis 
of CEB and validated the diagnoses based on information 
recorded in each patient’s individual medical record.
Danish national Patient registry
The DNPR contains information on patient contacts to all 
Danish hospitals, including hospital admissions since 1977 
and visits to all emergency rooms and outpatient hospital 
clinics since 1994.10 Each record includes, among other 
things, administrative measures, such as date and place of 
admission and discharge, along with coding of the primary 
reason for contact (primary diagnoses) and any conditions 
that contributed to the contact (secondary diagnoses). Diag-
noses are recorded at discharge by a medical doctor, using 
the eighth revision (ICD-8) until the end of 1993 and the 
Danish version of the ICD-10 thereafter.
Danish Pathology registry
Since 1997, all Danish Departments of Pathology have been 
legally obliged to report results from histopathological inves-
tigations to the DPR. The DPR was established to supplement 
registration of diseases in other registries (eg, DNPR) and 
contains information related to patient diagnosis and treat-
ment from both hospitals and the primary sector. Registration 
is performed by the investigating pathologist and is based 
on the Danish version of the Systematized Nomenclature of 
Medicine (SNOMED).11
Medical records
We searched medical records and extracted relevant informa-
tion on clinical descriptions, family histories, and results from 
histopathology and molecular genetic tests. We collected and 
managed data using the Research Electronic Data Capture 
(REDCap) tool hosted at Aarhus University. REDCap is 
a secure, web-based application designed to support data 
capture for research studies.12
Data collection and validation
We identif﻿ied all patients registered with a f﻿irst-time diagnosis 
of EB in the DNPR (ICD-8 code 757.23; ICD-10: Q81) or in 
the DPR (SNOMED-code S36300) during January 1, 1977, 
until December 31, 2015. The data extraction was specif﻿ied 
to also include ongoing contacts.
We validated the diagnoses against data collected from the 
medical records of patients identif﻿ied from two dermatologic 
departments, the Dermatologic Departments at Aarhus Uni-
versity Hospital and at Bispebjerg Hospital, and one regional 
hospital, Regional Hospital West Jutland. We based f﻿irst level 
of conf﻿irmation on clinical descriptions to exclude misdiag-
noses and/or misclassif﻿ications. Histological evaluation of 
level of separation served as a relevant paraclinical f﻿inding. 
We def﻿ined positive family history as one or more similar or 
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
23
0.
20
0 
on
 2
1-
M
ay
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2019:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
117
Validity of EB diagnoses in Denmark
conf﻿irmed cases in the family. The required clinical f﻿indings 
for f﻿irst level of conf﻿irmation of diagnosis were as follows: 
history of fragile skin with bullae; characteristic localiza-
tions; and age of onset before adulthood. Family history and 
relevant paraclinical f﻿indings provided conf﻿irmation of higher 
diagnostic specif﻿icity, with molecular genetic conf﻿irmation 
as the ultimate level. Consequently, we classif﻿ied identif﻿ied 
cases as rejected or probable, as specif﻿ied in Table 1. As a 
subgroup of probable cases, we further identif﻿ied those with 
the highest level of diagnostic certainty, including presence 
of histological, familial, or genetic evidence. We used other 
relevant clinical f﻿indings for subclassifying the conditions, 
including involvement of other epithelial surfaces than the 
skin; relative severity; involvement of teeth and/or gingiva; 
and other signif﻿icant specif﻿ic manifestations (Table S1).
One author, MHK, reviewed the medical records, 
extracted the relevant data, and classified diagnoses as 
described earlier. In cases where available material gave rea-
son for doubt (ie, wording or other causes), MS or UK (both 
with broad expertise in diagnosis and treatment of patients 
with genodermatoses) were consulted.
statistical analyses
We estimated the validity of f﻿irst-time CEB diagnoses in the 
DNPR and the DPR using the positive predictive value (PPV). 
The PPV was def﻿ined as the proportion of patients with a 
probable or conf﻿irmed diagnosis of CEB of those identif﻿ied 
as CEB through the aforementioned registries. We computed 
95% CIs using the Wilson’s method for groups consisting 
of 40 patients or more and the Jeffrey’s method for groups 
consisting of less than 40 patients.13
We computed PPVs for the total sample and according 
to the diagnosis coding systems. Additionally, we stratif﻿ied 
the PPV for ICD-10 diagnosis codes by the type of depart-
ment (specialized or regional), calendar year (before 2001, 
2001–2008, and 2009–2015), age at diagnosis (<1 year, 
1–5 years, 6–15 years, 16–64 years, and >64 years), sex, 
and by type of diagnosis (primary or secondary) and contact 
(admitted or outpatient hospital clinic).
We performed statistical analyses using Stata software 
(version 14.2; StataCorp LP, College Station, TX, USA).
Permits
The study was approved by the Danish Data Protection 
Agency (record number: 2013-58-0026; case number: 
1-16-02-668-15). The collection of data was approved 
by the National Board of Health (case number: 3-3013-
1606/1). According to Danish legalization, written informed 
consent was not required. All investigations were carried 
out in accordance with the principles of the Declaration 
of Helsinki.
Results
We identif﻿ied 618 patients diagnosed with EB in the DNPR 
(n=512) and the DPR (n=106) during the study period. 
Among them, 116 patients (18.8%) were registered at one of 
three departments selected for validation (Figure 1). Medi-
cal records were available for 96 patients (82.8%): 90.9% at 
Aarhus Dermatological Department, 69.0% at Bispebjerg 
Dermatological Department, and 100% at Regional Hospital 
Table 1 Criteria used for validating diagnoses of congenital epidermolysis bullosa
Classification Criteria
Probable history of fragile skin with bullae + characteristic localizations + onset before adulthood
Confirmed Molecular genetic confirmation; histological evidence (level of separation) including probable criteria; or positive family 
history (one or more similar or confirmed cases in the family) including probable criteria
rejected none of the above
Total population
n=618
Population sought
validated
n=116
Records not available
n=20
Records validated
n=96
Probable cases of
CEB
n=60
Confirmed cases of
CEB
n=32
Records rejected as
CEB
n=36
Figure 1 Flowchart illustrating the validation process of the CEB diagnoses.
Abbreviation: CEB, congenital epidermolysis bullosa.
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West Jutland. We were able to retrieve as much as 100% of 
the ICD-10 identif﻿ied records for the period of 2009–2015 
(Table S2). For all patients with medical records available for 
review, the median age at f﻿irst-time diagnosis was 23 years 
(IQR 5–40 years) and 42.7% were female (Table 2). The 
total study population had higher median age at diagnosis 
and a higher proportion of females (Table 2). For the ICD-
10-coded validation sample, we found similar distribution 
of characteristics for those with nonmissing and missing 
medical records (Table S3).
In the validation sample, we classif﻿ied 36 diagnoses (38%) 
as rejected: 22 (23%) represented other diagnoses than EB, 
13 (14%) had insuff﻿icient evidence to satisfy validation, and 
in one case (1%), available information was too scarce to 
suggest any diagnosis. Of those classif﻿ied as other diagnoses, 
16 were acquired EB, one was a blister in a factitious disor-
der, one was toxic epidermal necrolysis, one was x-linked 
ichthyosis, one was neurof﻿ibromatosis, one was localized 
epidermolytic rash, and one was a traumatic blister. Among 
records where available data were insuff﻿icient to suggest other 
diagnoses or to satisfy validation, 12 had evidence suggesting 
CEB but record information did not fulf﻿ill the listed criteria 
for probable CEB (Table 1) and one had clinical evidence 
suggesting cutaneous vasculitis.
This medical record review yielded an overall PPV for 
CEB of 62.5% (95% CI: 52.5–71.5), including probable 
and conf﻿irmed diagnoses (Table 3). The PPV decreased to 
33.3% (95% CI: 24.7–43.2) when limiting to conf﻿irmed 
diagnoses, exclusively. When comparing the three coding 
systems, the PPVs for probable diagnoses were 30.8% (95% 
CI: 11.4–57.7) for ICD-8, 76.7% (95% CI: 65.8–84.9) for 
ICD-10, and 0.0% (95% CI: 0.0–21.7) for SNOMED. For 
conf﻿irmed diagnoses, the corresponding values were 15.4% 
(95% CI: 3.3–40.9), 41.1% (95% CI: 30.5–52.6), and 0.0% 
(95% CI: 0.0–21.7).
Results from analyses restricted to ICD-10 codes are 
shown in Table 3. For the ICD-10 codes, the PPVs for the 
probable diagnoses at specialized dermatological depart-
ments and the regional department were 78.3% (95% CI: 
67.2–86.4) and 50.0% (95% CI: 12.3–87.7), respectively. 
For the conf﻿irmed diagnoses, the corresponding PPVs were 
40.6% (95% CI: 29.8–52.4) and 50.0% (95% CI: 12.3–87.7). 
We found no clear variation in PPVs according to the calen-
dar period of diagnosis. We observed comparable PPVs in 
subgroups of sex and age. The lowest estimates were found 
at the extremes of the age categories. The PPVs including 
probable diagnosis was 81.3% (95% CI: 70.0–88.9) for 
primary diagnoses and 44.4% (95% CI: 17.3–74.6) for 
secondary diagnoses. This difference was less pronounced 
for conf﻿irmed diagnoses: 42.2% (95% CI: 30.9–54.4) for 
primary diagnoses and 33.3% (95% CI: 10.4–65.2) for sec-
ondary diagnoses. Similarly, the PPVs for probable diagnoses 
were 78.6% (95% CI: 67.6–86.6) for outpatients and 33.3% 
(95% CI: 3.9–82.3) for inpatients. Corresponding PPVs for 
conf﻿irmed diagnoses were 41.4% (95% CI: 30.6–53.1) and 
33.3% (95% CI: 3.9–82.3). A more detailed comparison of 
data from the two dermatological departments is provided in 
Tables S4–S6. In short, the distribution of diagnosis coding 
Table 3 PPV for the coding of epidermolysis bullosa in the DnPr and the DPr
Coding system Sample, n Probable, n Confirmed, n PPV (95% CI) for 
probable
PPV (95% CI) 
for confirmed
Total 96 60 32 62.5 (52.5–71.5) 33.3 (24.7–43.2)
ICD-8 13 4 2 30.8 (11.4–57.7) 15.4 (3.30–40.9)
ICD-10 73 56 30 76.7 (65.8–84.9) 41.1 (30.5–52.6)
snOMED 10 0 0 0.00 (0.00–21.7) 0.00 (0.00–21.7)
Abbreviations: DnPr, Danish national Patient registry; DPr, Danish Pathology registry; PPV, positive predictive value; snOMED, systematized nomenclature of Medicine.
Table 2 Demographics and distribution of the total study population, the validation sample, and missing records
Characteristic Total population, n (%) Validated population, n (%) Missing records, n (%)
Total 618 (100) 96 (15.5 of total) 20
Sex (% female) 309 (50.0) 41 (42.7) 10 (50.0)
Median age at diagnosis (IQR), years 30 (4–60) 23 (5–40) 35 (11–66)
ICD-10 384 (62.1) 73 (76.0) 9 (45.0)
ICD-8 128 (20.7) 13 (13.5) 1 (5.0)
snOMED 106 (17.2) 10 (10.4) 10 (50.0)
Abbreviation: snOMED, systematized nomenclature of Medicine.
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systems differed slightly at the respective departments, but 
the characteristics were similar overall (Table S4) and when 
restricting to those recorded with the ICD-10 system (Table 
S5). We also found comparable PPVs in subgroup analyses 
for the two dermatological departments (Table S6).
At the four-digit ICD-10 level, we found PPVs of 83.3% 
(95% CI: 67.3–93.3) for EB simplex and 100% (95% CI: 
85.7–100) for dystrophic EB (Table S7). For the remaining 
ICD diagnoses (junctional and others), we observed PPVs 
of 0, as records found yielded no f﻿indings of probable during 
this validation.
Discussion
In this study, we investigated the validity of the coding of CEB 
in the DNPR and the DPR. This included the following three 
diagnosis coding systems: ICD-8, ICD-10, and SNOMED. 
We estimated the coding systems’ validity for probable 
diagnoses, where we required only clinical f﻿indings, and for 
conf﻿irmed diagnoses, requiring positive family history and/
or conclusive paraclinical f﻿indings. In the daily clinical set-
ting, diagnoses of most cases of EB are based primarily on 
clinical f﻿indings. Consequently, the conf﻿irmed group provides 
insights into how often further investigations are deemed 
necessary to be certain of the diagnosis, or when it judged 
to affect the prognosis and/or the treatment. The probable 
group on the other hand is the most relevant measure of the 
precision of the clinical diagnostic process and therefore we 
focus mainly on this subset subsequently.
The PPVs for ICD-10 diagnoses were higher than for 
ICD-8 and SNOMED and were particularly high for the 
specialized dermatological departments. In fact, only a 
small proportion of CEB patients were identif﻿ied through 
the DPR, and we were not able to identify any as probable. 
This f﻿inding may be explained by avoidance in using histopa-
thology in diagnosis of this population consisting of mainly 
young children and infants with a positive family history. 
Regardless, identifying CEB cases through the DPR is a 
poor choice of method. Similarly, we note that the number 
of patients identif﻿ied in regional departments was low (n=4), 
limiting precision. When stratifying by age at diagnosis, 
PPV improved as age decreased; however, only at age above 
1 year. The high PPV at low age may indicate that the more 
severe phenotypes, that are easier to diagnose, are seen 
earlier in life with few differential diagnoses. The reason 
for PPV dropping at age below 1 year is unknown, but may 
be attributed to poor recording of relevant manifestations in 
the medical records at the low patient age. When stratifying 
by calendar year, we observed subtle differences between 
the time periods (Table S4). At both Aarhus and Bispebjerg 
Dermatological Departments, we found the lowest PPV in 
the period from 2001 to 2008. However, while there was 
a trend toward higher PPVs, and thus higher diagnostic 
precision in the more recent time periods in Aarhus, this 
was not clearly the case at Bispebjerg. The reason for this is 
unknown. There is a noteworthy difference between the PPVs 
of primary and secondary diagnoses. The PPV for primary 
diagnoses is approximately twice as good as the secondary 
diagnoses (Table 4). This difference is expected as second-
ary diagnoses may not be conf﻿irmed or focused on during 
treatment of a patient. Moreover, we note that EB rarely is 
a secondary f﻿inding, as it was the primary reason for patient 
contact for 64 of the 73 validated cases. EB patients were 
diagnosed at an outpatient hospital clinic assuming that EB 
was the primary cause for the consultation.
A recent systematic review validating codes from the 
DNPR have found that PPVs herein ranges from 15% to 
100%, emphasizing the need for validation of diagnoses 
before using data for research purposes.9 To our knowl-
edge, the validity of EB diagnoses in the Danish registries 
has not been investigated, and the results from the study 
presented here show PPVs in the range low to medium in 
comparison.
There are some methodological limitations of this 
study that should be mentioned. First, a small proportion 
of medical records could not be retrieved. However, it is 
unlikely that the absence of records depends on factors 
affecting the PPV, as we observed similar characteristics 
for validated and missing records. When looking at the 
comparability between the validated population and the 
total population, the demographics and diagnosis system 
distribution differed to some extent. The validated popula-
tion consisted of a larger proportion of ICD-10 diagnoses, 
a lower proportion of females, and a lower median age at 
diagnosis. This may be explained by the predominance of 
dermatological departments, where more severe cases are 
seen, in the validation sample. In general, it is question-
able what can be inferred about diagnoses from regional 
departments, as the number of cases validated here was 
quite low. Our overall f﻿indings are most likely not generaliz-
able to non-specialized departments. Second, we included 
records that had insuff﻿icient evidence to satisfy validation or 
where available material was too scarce to suggest another 
diagnosis, which probably results in an underestimation 
of PPVs. Conversely, as the clinical manifestations differ 
widely both within and between diagnoses, our criteria for 
“probable” diagnoses needed to be quite inclusive, which 
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would result in an overestimation of PPVs. We sought to 
minimize this bias by identifying the most common mis-
diagnosis (acquired forms) and, as aforementioned, not 
excluding records with unsatisfactory data. Third, records 
were evaluated by only one person. Fourth, the study sample 
reflects the rarity of CEB and limits the study conclusions 
that can be drawn from in subgroup analyses. In particular, 
the specif﻿ic diagnoses are so rare that interpretation and 
generalizability must be done with caution. Finally, we were 
not able to estimate completeness of diagnoses. It is pos-
sible that cases with milder disease manifestations, that are 
inherited dominantly, are never seen at a hospital because 
the condition and its treatment are known in the family 
and is manageable by the general practitioner. Validity of 
results of four-digit ICD-10 level diagnoses is limited to the 
more common forms identif﻿ied, which are EB simplex and 
dystrophic EB, leaving junctional EB and the nonspecif﻿ied 
group with results of low validity.
The strength of this study relies on the ability to identify 
patients nationwide from a population-based cohort using 
the Danish CPR number, thus avoiding selection bias of the 
primary data. Also, we were able to retrieve most medical 
records of the identif﻿ied patients, yielding a validation 
sample of 16% of the total population. We focused on vali-
dating diagnoses from dermatological departments, because 
insights into the validity of diagnoses from dermatological 
departments are particularly important, eg, when planning 
future observational studies or clinical trials, which will 
typically be based in a setting where EB patients are diag-
nosed and followed. The registration of diagnosis at Danish 
hospitals is performed manually and often involves only 
one or a few doctors, which makes the systems susceptible 
to miscoding. This point may explain why many registra-
tions were either acquired forms or completely unrelated 
diagnoses having ICD-10 codes that were numerically 
related to the ones investigated. A method for rooting out 
misclassif﻿ications is to require two or more independent 
registrations of the diagnosis of interest. Such an approach 
was used in a study investigating acromegaly, which showed 
an increase in PPV although this came at the expense of the 
total number of conf﻿irmed cases.14
The DNPR and the DPR are broad administrative and 
research registries comprising any condition leading to 
hospital contact or pathological examination, respectively. 
They are invaluable data sources for research, and high 
validity has been reported for many common diseases.9 
However, as suggested by this study, the registries may be 
suboptimal for studying conditions, such as CEB, which is 
Table 4 Results for PPV for probable and confirmed ICD-10 epidermolysis bullosa diagnoses stratified by department type, sex, age 
at diagnosis, calendar year, diagnosis type, and patient type
Characteristic Count, n Probable, n Confirmed, n PPV (95% CI) 
for probable
PPV (95% CI) 
for confirmed
Department type
regional 4 2 2 50.0 (12.3–87.7) 50.0 (12.3–87.7)
specialized 69 54 28 78.3 (67.2–86.4) 40.6 (29.8–52.4)
sex
Male 42 33 19 78.6 (64.1–88.3) 45.2 (31.2–60.1)
Female 31 23 11 74.2 (57.1–87.0) 35.5 (20.5–53.0)
Age at diagnosis (years)
<1 6 3 2 50.0 (16.6–83.3) 33.3 (7.7–71.4)
1–5 17 16 8 94.1 (75.6–99.4) 47.1 (25.4–69.7)
6–15 11 8 4 72.7 (43.5–91.7) 36.4 (13.7–65.2)
16–64 35 27 16 77.1 (61.5–88.6) 45.7 (30.1–62.0)
>64 4 2 0 50.0 (12.3–87.7) 0.0 (0.0–44.5)
Calendar year
<2001 22 16 8 72.7 (52.2–87.7) 36.4 (18.9–57.1)
2001–2008 14 10 7 71.4 (45.5–89.5) 50.0 (25.9–74.1)
2009–2015 37 30 15 81.1 (66.4–91.1) 40.5 (25.9–56.6)
Type of diagnosis
Primary 64 52 27 81.3 (70.0–88.9) 42.2 (30.9–54.4)
secondary 9 4 3 44.4 (17.3–74.6) 33.3 (10.4–65.2)
Patient type
Outpatient 70 55 29 78.6 (67.6–86.6) 41.4 (30.6–53.1)
admitted 3 1 1 33.3 (3.9–82.3) 33.3 (3.9–82.3)
Abbreviation: PPV, positive predictive value.
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rare and diagnostically challenging for physicians without 
experience in recognizing and treating genodermatoses. 
Furthermore, relevant clinical and paraclinical details, eg, 
manifestations, severity, family history, and identif﻿ied muta-
tions, are not recorded in the general registries. These limi-
tations underscore the need for a national disease-specif﻿ic 
registry for CEB, such as The International Registry of 
Dystrophic Epidermolysis Bullosa Patients and Associated 
COL7A1 Mutations15and The National Epidermolysis Bul-
losa Registry,16 with validated diagnoses from specialized 
departments and requirements of details. This work has 
already been initiated with the recent establishment of The 
Danish Database for Genodermatoses,17 which has been 
driven in part by this work.
Conclusion
This study found that PPVs for diagnoses of CEB in the 
DNPR and DPR ranged from very low for ICD-8 and 
SNOMED codes to average for ICD-10 codes. Further-
more, when restricting to ICD-10 codes, the validity of the 
diagnoses was much higher for diagnoses from dermato-
logical departments compared with a regional department. 
Consequently, CEB diagnoses identif﻿ied through the Danish 
national health registries should be used with caution and if 
used should be restricted to ICD-10 codes from specialized 
dermatological departments.
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Supplementary materials
Table S1 List of specific clinical symptoms and findings related to 
and indicating specific subtype of congenital epidermolysis bullosa
Clinical findings of significance
itch Milia
Poikiloderma Keratoderma
Photosensitivity aplasia cutis
anonychia Vocal cord involvement
Mucosal involvement Pseudosyndactyly
hyper granulation tissue Pyloric atresia
Erosions Pigmentation scarring
Pulmonary involvement renal involvement
Muscular dystrophy  
Notes: The list was chosen as representative presentation for the wide range 
of specific subtypes of congenital epidermolysis bullosa by review of the latest 
consensus report. no single item on the list is pathognomonic but must be seen 
in correlation to other clinical and paraclinical findings.1 all patients were required 
to have “bullae” mentioned in the medical record to be considered probable or 
confirmed. Data from Fine JD, Bruckner-Tuderman L, Eady RA, et al.1
Table S2 Proportion of patients identified by ICD-10 codes who had medical records available for validation, overall, and by hospital 
and calendar period of diagnosis
Calendar  
period
Hospital
Aarhus Bispebjerg Herning Total
Sought, n Found, n (%) Sought, n Found, n (%) Sought, n Found, n (%) Sought, n Found, n (%)
<2001 14 14 (100) 9 4 (44.4) 4 4 (100) 27 22 (81.5)
2001–2008 10 10 (100) 8 4 (50) 0 0 18 14 (77.8)
2009–2015 20 20 (100) 17 17 (100) 0 0 37 37 (100)
Total 44 44 (100) 34 25 (73.5) 4 4 (100) 82 73 (89.0)
Table S3 Comparison of characteristics of nonmissing records 
and missing records for those from the validations sample, ICD-
10 diagnoses only
Characteristic Nonmissing 
records, n (%)
Missing 
records, n (%)
Total 73 (100) 9 (100)
Calendar period 
of diagnosis
  
<2001 22 (30.1) 5 (55.6)
2001–2008 14 (19.2) 4 (44.4)
2009–2015 37 (50.7) 0 (0.0)
Departments   
specialized 69 (94.5) 9 (100)
regional 4 (5.5) 0 (0.0)
age at diagnosis 
(years)
  
<1 6 (8.2) 0 (0.0)
1–5 17 (23.3) 2 (22.2)
6–15 11 (15.1) 4 (44.4)
16–64 35 (47.9) 2 (22.2)
>64 4 (5.5) 1 (11.1)
Type of diagnosis   
Primary 64 (87.7) 8 (88.9)
secondary 9 (12.3) 1 (11.1)
Patient type   
Outpatient 70 (95.9) 9 (100)
admitted 3 (4.1) 0 (0.0)
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Table S6 Comparing the PPV of the two dermatological 
departments in the presented subgroups
Characteristic Aarhus Bispebjerg
n PPV (95% CI) n PPV (95% CI)
Total 44 84.1 (70.6–92.1) 25 68.0 (48.5–83.6)
sex     
Males 28 85.7 (69.5–95.0) 14 64.3 (38.5–84.9)
Females 16 81.3 (57.9–94.4) 11 72.7 (43.5–91.7)
age at diagnosis     
<1 1 100 (14.7–100) 2 0 (0–66.7)
1–5 10 100 (78.3–100) 7 85.7 (49.9–98.4)
6–15 6 66.7 (28.6–92.3) 5 80.0 (37.3–97.7)
16–64 24 83.3 (65.1–94.1) 11 63.6 (34.8–86.3)
>64 3 66.7 (17.7–96.1) 0 –
Calendar year     
<2001 14 78.6 (53.1–93.6) 4 75.0 (28.4–97.2)
2001–2008 10 80.0 (49.7–95.6) 4 50.0 (12.3–87.7)
2009–2015 20 90.0 (71.6–97.9) 17 70.6 (47.0–87.8)
Type of diagnosis     
Primary 40 85.0 (30.1–95.4) 22 77.3 (57.1–90.8)
secondary 4 75.0 (28.4–97.2) 3 0 (0–53.6)
Patient type     
Outpatient 43 86.0 (72.7–93.4) 25 68.0 (48.5–83.6)
admitted 1 0.0 (0.0–85.3) 0 –
Abbreviation: PPV, positive predictive value.
Table S4 Demographic characteristics between validated 
population from aarhus and Bispebjerg Dermatological 
Departments and the distribution of the diagnosis code systems 
(ICD-8, ICD-10, and SNOMED), sex, and median age at diagnosis
Characteristic Aarhus 
department, n (%)
Bispebjerg 
department, n (%)
Total 60 (100) 29 (100)
ICD-8 9 (15.0) 1 (3.5)
ICD-10 44 (73.3) 25 (77.5)
snOMED 7 (11.7) 3 (10.3)
Sex n female (% 
female)
20 (33.3) 15 (51.7)
Median age at 
diagnosis (IQR)
26 (6–43) 15 (3–34)
Abbreviation: snOMED, systematized nomenclature of Medicine.
Table S5 Demographic and descriptive parameters of the ICD-
10 coded populations of the two specialized dermatological 
departments
Characteristic Aarhus 
department, n (%)
Bispebjerg 
department, n (%)
Total 44 (100) 25 (100)
sex   
Males 28 (63.7) 11 (44.0)
Females 16 (36.4) 14 (56.0)
age at diagnosis 
(years)
  
<1 1 (2.3) 2 (8.0)
1–5 10 (22.7) 7 (28.0)
6–15 6 (13.6) 6 (20.0)
16–64 24 (54.6) 11 (44.0)
>64 3 (6.8) 0 (0.0)
Calendar year   
<2001 14 (31.8) 4 (16.0)
2001–2008 10 (22.7) 4 (16.0)
2009–2015 20 (45.5) 17 (68.0)
Type of 
diagnosis
  
Primary 40 (90.9) 22 (88.0)
secondary 4 (9.1) 3 (12.0)
Patient type   
Outpatient 43 (97.7) 25 (100)
admitted 1 (2.3) 0 (0.0)
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Table S7 Distribution of specific ICD-10 EB diagnoses classified as probable against the new ICD-10 diagnosis based on validation 
including the PPV for each
New ICD-10 
diagnoses (after 
validation)
Registered EB diagnoses (ICD-10), n PPV (95% CI) at 
4-digit level  
(= complete ICD-10 
code agreement)
Complete 
distribution 
of validated 
records, n
Q81.0 Q81.1 Q81.2 Q81.8 Q81.9
Q81.0 25 0 0 0 9 83.3 (67.3–93.3) 34
Q81.1 0 0 0 0 0 na 0
Q81.2 0 0 16 0 5 100 (85.7–100) 21
Q81.8 1 0 0 0 0 0.0 (0.0–53.6) 1
Q81.9 0 0 0 0 0 na 0
Validated 
(column total), 
n
30 2 16 3 22 73 73
Total column 
probable, n
26 0 16 0 14 41 56
Column PPVs 
(95% CI)
86.7 
(71.3–95.3)
0.0 
(0.0–66.7)
100 
(85.7–100)
0.0 
(0.0–53.6)
63.6 
(42.9–81.1)
56.2 (44.8–67.0) 76.7 (65.8–84.9)
Abbreviations: EB, epidermolysis bullosa; PPV, positive predictive value; Q81.0, epidermolysis bullosa simplex; Q81.1, epidermolysis bullosa letalis; Q81.2, epidermolysis 
bullosa dystrophica; Q81.8, other epidermolysis bullosa; Q81.9, epidermolysis bullosa unspecified.
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